Physician profile
Hakeem Sam
NPI 1134315971
$1,800.70
in general payments reported to CMS, 2019-2025
26 companies · $428 in 2025
The $428 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $630 · 2020: $131 · 2021: $48.58 · 2022: $123 · 2023: $221 · 2024: $219 · 2025: $428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $796 · Education: $72.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $796.45 |
| Education | $72.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $237.96 | 2019-2025 | Rinvoq |
| Janssen Biotech, INC. | $197.37 | 2019-2024 | Tremfya |
| Mimedx Group, INC. | $194.31 | 2025 | |
| Novartis Pharmaceuticals Corporation | $145.81 | 2019-2025 | |
| Pfizer INC. | $142.69 | 2019-2023 | |
| Galderma Laboratories, L.P. | $88.41 | 2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $83.72 | 2019-2022 | |
| Organogenesis INC. | $78.91 | 2023-2024 | Puraply |
| Genzyme Corporation | $77.43 | 2019-2025 | |
| Kerecis Limited | $53.73 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Genentech USA, INC. | $53.30 | 2019-2020 | |
| Amgen INC. | $50.14 | 2019-2025 | Otezla |
| Celgene Corporation | $48.56 | 2019 | |
| Dermira, INC. | $43.86 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $40.38 | 2022-2024 | Sotyktu |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $35.86 | 2025 | Libtayo |
| Lilly USA, LLC | $35.13 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $34.22 | 2019 | |
| Misonix INC | $33.52 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $26.03 | 2019 | |
| Incyte Corporation | $19.61 | 2022 | |
| Biofrontera INC. | $19.25 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Aclaris Therapeutics, INC. | $16.26 | 2019 | |
| Vyne Pharmaceuticals INC. | $15.63 | 2020 | |
| Conmed Corporation | $14.65 | 2023 | Visiclear |
| Dusa Pharmaceuticals, INC. | $13.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hakeem Sam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.